Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Nanobiotix S.A. NBTX
$4.74
-$0.44 (-9.37%)
На 18:03, 12 мая 2023
Ключевые показатели
-
Marketcap
197643105.00000000
-
week52high
7.76
-
week52low
1.75
-
Revenue
4776000
-
P/E TTM
-4
-
Beta
1.78778600
-
EPS
-1.67000000
-
Last Dividend
0.00000000
-
Next Earnings Date
29 мар 2023 г. в 04:00
Описание компании
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Evercore ISI Group | Outperform | 06 янв 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
NANOBIOTIX to Present at the 5th Annual Evercore ISI HealthCONx Conference
GlobeNewsWire
15 ноя 2022 г. в 16:15
PARIS and CAMBRIDGE, Mass., Nov. 15, 2022 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that Laurent Levy, co-founder and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in a virtual fireside chat at the 5th annual Evercore ISI HealthCONx Conference on Thursday, December 1, 2022, at 9:15 AM ET / 3:15 PM CET.
Nanobiotix S.A. (NBTX) Q3 2022 Earnings Call Transcript
Seeking Alpha
11 ноя 2022 г. в 11:12
Nanobiotix S.A. (NASDAQ:NBTX ) Q3 2022 Earnings Call Transcript November 10, 2022 8:00 AM ET Company Participants Kate Mcneil - Senior Vice President, Investor Relations Laurent Levy - Co-Founder & Chief Executive Officer Bart Van Rhijn - Chief Financial Officer Conference Call Participants Mike DiFiore - Evercore Clément Bassat - BNP Paribas Kate Mcneil Thank you, operator.
NANOBIOTIX to Present at the Jefferies London Healthcare Conference
GlobeNewsWire
31 окт 2022 г. в 16:15
PARIS and Cambridge, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that Laurent Levy, co-founder and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in a fireside chat at the Jefferies London Healthcare Conference at 5:00 PM GMT/12:00 PM ET on Tuesday, November 15, 2022.
NANOBIOTIX to Announce Third Quarter 2022 Financial Results on November 9, 2022
GlobeNewsWire
27 окт 2022 г. в 16:15
Conference Call and Webcast to be Held at 8:00 AM ET / 2:00 PM CET on November 10, 2022 Conference Call and Webcast to be Held at 8:00 AM ET / 2:00 PM CET on November 10, 2022
Nanobiotix S.A (NBTX) Q2 2022 Earnings Call Transcript
Seeking Alpha
29 сент 2022 г. в 14:08
Nanobiotix S.A (NASDAQ:NBTX ) Q2 2022 Earnings Conference Call September 29, 2022 8:00 AM ET Company Participants Laurent Levy - Co-Founder, CEO Bart Van Rhijn - CFO Kate McNeil - IR Conference Call Participants Jon Miller - Evercore Suzanne van Voorthuizen - Kempen Kate McNeil Good afternoon and good morning. And welcome to Nanobiotix Conference Call to discuss our First Half 2022 Financial and Operational results.